Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 5/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51959 | 0.93 | CYP2C9 (0.39) | CYP2C9KCNH2MMP13 | |
| SCHEMBL52913 | 0.91 | CYP2C9 (0.44) | CYP2C9KCNH2MMP13DGAT1CXCR3 | |
| SCHEMBL52619 | 0.90 | CYP2C9 (0.47) | CYP2C9KCNH2PDE5AMAPK1 | |
| SCHEMBL52811 | 0.84 | CYP2C9 (0.46) | CYP2C9KCNH2MMP13CXCR3 | |
| SCHEMBL63517 | 0.84 | CYP2C9 (0.42) | CYP2C9KCNH2CXCR3 | |
| SCHEMBL52472 | 0.84 | CYP2C9 (0.43) | CYP2C9KCNH2MMP13 | |
| SCHEMBL52059 | 0.83 | CYP2C9 (0.45) | CYP2C9KCNH2MMP13 | |
| SCHEMBL52357 | 0.83 | CYP2C9 (0.48) | CYP2C9KCNH2MAPK1 | |
| SCHEMBL52289 | 0.83 | CYP2C9 (0.48) | CYP2C9KCNH2MAPK1 | |
| SCHEMBL51736 | 0.83 | CYP2C9 (0.48) | CYP2C9KCNH2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | CYP2C9 602/4885KCNH2 3969/4885PDE5A 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.